Founded in 2017, the proteomics Seer (Nasdaq:SEER) is building up a growing roster of customers, including pharma and biotech companies, translational and academic labs and CROs. Applications of its technology include biomarker discovery, target identification and multiomics research for cancer or other complex disease detection.
Recently, Weill Cornell Medicine and privately-held SpaceX used Seer’s proteome profiling technology to identify 50 differentially abundant proteins in astronauts postflight. In all, 22 proteins were upregulated, and 28 were downregulated across six time points collected before, during and after the flight. The proteins were “differentially changed as a function of a flight,” said Seer CEO Omid Farokhzad in a recent interview. The research could lead to a better understanding of the impact of space travel on people.
Another Seer customer, Evotec (Nasdaq:EVO), used Seer technology to analyze 105 samples from patients w…